How to appeal an Asthma Biologics (Xolair / Fasenra) denial
Asthma-biologic denials target the high-cost J-code drug, step-therapy, and the biomarker criteria — payers require documented severe or eosinophilic asthma, failed inhaled therapy, and specific IgE or eosinophil thresholds before covering the drug the practice buys.
Common code: J2357 (omalizumab), J0517 (benralizumab), J2182 (mepolizumab), J2786 (reslizumab) + 96372/96401 adminWhy it gets denied
- The eosinophil count or IgE level required by the policy wasn't documented
- Step-therapy (a high-dose ICS/LABA trial) wasn't shown
- Prior authorization lapsed or didn't cover the dose/interval
- J-code units didn't reconcile to the weight- or level-based dose, or waste (JW) wasn't billed
What overturns it
- Document the biomarker (eosinophils, IgE) and the failed controller-therapy trial that meet the coverage criteria
- Keep prior auth current for the exact agent, dose, and interval and tie it to the claim
- Reconcile J-code units to the administered dose and bill waste correctly with JW/JZ
- Pursue the exception when the documented phenotype supports the biologic
Worth appealing? These are buy-and-bill drugs running hundreds to thousands per dose the practice fronts, so a denial is direct capital exposure. They're recoverable when the biomarker criteria and prior therapy are documented.
Common questions
How do I appeal an Asthma Biologics (Xolair / Fasenra) denial?
Asthma-biologic denials target the high-cost J-code drug, step-therapy, and the biomarker criteria — payers require documented severe or eosinophilic asthma, failed inhaled therapy, and specific IgE or eosinophil thresholds before covering the drug the practice buys. To overturn it: document the biomarker (eosinophils, IgE) and the failed controller-therapy trial that meet the coverage criteria; keep prior auth current for the exact agent, dose, and interval and tie it to the claim; reconcile J-code units to the administered dose and bill waste correctly with JW/JZ; pursue the exception when the documented phenotype supports the biologic.
Why do Asthma Biologics (Xolair / Fasenra) claims get denied?
The eosinophil count or IgE level required by the policy wasn't documented; Step-therapy (a high-dose ICS/LABA trial) wasn't shown; Prior authorization lapsed or didn't cover the dose/interval; J-code units didn't reconcile to the weight- or level-based dose, or waste (JW) wasn't billed.
Is a Asthma Biologics (Xolair / Fasenra) denial worth appealing?
These are buy-and-bill drugs running hundreds to thousands per dose the practice fronts, so a denial is direct capital exposure. They're recoverable when the biomarker criteria and prior therapy are documented. You pay 25% only on what's recovered, so there's no cost to working the winnable ones.
See how many Asthma Biologics (Xolair / Fasenra) denials you wrote off.
A free assessment shows your real recoverable number. No risk, paid only on what we recover.